OncoC4 is focused on developing innovative cancer therapies that target novel immune checkpoints, specifically CTLA-4, CD24, and Siglec, to enhance the immune response against hard-to-treat cancers. Their CTLA-4 program, featuring the antibody gotistobart, aims to address immunotherapy-resistant non-small cell lung cancer and other advanced tumors. The company is also exploring Siglec signaling to improve cancer immunity while minimizing adverse effects associated with existing treatments. Additionally, their CD24 platform targets a specific neo-CD24 epitope found only on cancer cells, which allows for the potential treatment of a wide range of solid and hematologic malignancies.

OncoC4's pipeline showcases a diverse array of therapeutic modalities, including monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and CAR T-cell therapies. This multifaceted approach is designed to tackle the complexities of various tumors, with ongoing clinical trials aimed at evaluating the safety and efficacy of their treatments across multiple cancer types. The company is committed to advancing its research and development efforts to provide safer, more effective, and durable cancer therapies, ultimately striving to improve patient outcomes in the fight against cancer.

United States

Based in Rockville, Maryland, OncoC4 is a privately-held, clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of novel biologicals for cancer treatment.

OncoC4

Company Details